https://www.selleckchem.com/pr....oducts/ins018-055-is
Recipient adverse events were rare (0·6%) and of minor severity. In end-of-life transfused patients with haematologic malignancies, approaching death is associated with an increased number of platelet transfusions and bleeding events, while platelet recovery and transfusion intervals are reduced. Such findings, together with further evaluations, may contribute to informing best practices for these patients. In end-of-life transfused patients with haematologic malignancies, approaching death is associated with an increased
Like
Comment
Share
